LY3039478 is an orally bioavailable γ-secretase inhibitor that is effective in a range of cancers in Phase 1 studies.42 EOC with high JAG2+TANs infiltration can be used as a marker for selecting patients for Notch targeted therapy. The gene discussed is JAG2; the disease is cancer.